Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.32 USD | +0.25% | -5.46% | +11.90% |
13/05 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
10/05 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.90% | 1.65B | |
+7.23% | 113B | |
+11.18% | 106B | |
+0.32% | 22.27B | |
-11.95% | 22.22B | |
-5.99% | 19.43B | |
-37.85% | 17.87B | |
-6.32% | 17.24B | |
+6.89% | 14.29B | |
+34.93% | 12.52B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment